GNOM vs. SRVR
GNOM (Global X Genomics & Biotechnology ETF) and SRVR (Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF) are both exchange-traded funds - GNOM is a Health & Biotech Equities fund tracking the Solactive Genomics Index, while SRVR is a REIT fund tracking the Benchmark Data & Infrastructure Real Estate SCTR Index. Both are passively managed. Over the past 5 years, GNOM returned -10.20%/yr vs -0.81%/yr for SRVR. At a 0.49 correlation, their price movements are largely independent. GNOM charges 0.50%/yr vs 0.60%/yr for SRVR.
Performance
GNOM vs. SRVR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GNOM achieves a 7.81% return, which is significantly lower than SRVR's 19.79% return.
GNOM
- 1D
- 1.99%
- 1M
- 5.82%
- YTD
- 7.81%
- 6M
- 6.65%
- 1Y
- 54.21%
- 3Y*
- -0.94%
- 5Y*
- -10.20%
- 10Y*
- —
SRVR
- 1D
- -1.79%
- 1M
- -2.74%
- YTD
- 19.79%
- 6M
- 20.69%
- 1Y
- 11.19%
- 3Y*
- 8.85%
- 5Y*
- -0.81%
- 10Y*
- —
GNOM vs. SRVR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 7.81% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 1.56% |
SRVR Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF | 19.79% | -1.99% | 2.70% | 6.84% | -31.90% | 22.31% | 11.99% | 14.32% |
Correlation
The correlation between GNOM and SRVR is 0.43, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.43 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.46 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.51 |
Correlation (All Time) Calculated using the full available price history since Apr 11, 2019 | 0.49 |
The correlation between GNOM and SRVR has been stable across timeframes, ranging from 0.43 to 0.51 - a consistent structural relationship.
GNOM vs. SRVR - Sectors Allocation Comparison
Sectors
GNOM
SRVR
Healthcare
-
Technology
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
Financial Services
-
Industrials
-
Real Estate
-
Utilities
-
Healthcare
GNOM
SRVR
-
Technology
GNOM
SRVR
Basic Materials
GNOM
-
SRVR
Communication Services
GNOM
-
SRVR
Consumer Cyclical
GNOM
-
SRVR
-
Consumer Defensive
GNOM
-
SRVR
-
Energy
GNOM
-
SRVR
Financial Services
GNOM
-
SRVR
Industrials
GNOM
-
SRVR
Real Estate
GNOM
-
SRVR
Utilities
GNOM
-
SRVR
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM vs. SRVR — Risk / Return Rank
GNOM
SRVR
GNOM vs. SRVR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF (SRVR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOM | SRVR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.39 | ||
| Sortino ratioReturn per unit of downside risk | +1.86 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.13 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | 3.00 | 0.76 | +2.24 |
| Martin ratioReturn relative to average drawdown | 8.62 | 1.64 | +6.98 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GNOM | SRVR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.06 | 0.67 | +1.39 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.31 | -0.04 | -0.26 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.09 | 0.30 | -0.38 |
Drawdowns
GNOM vs. SRVR - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, which is greater than SRVR's maximum drawdown of -40.99%. Use the drawdown chart below to compare losses from any high point for GNOM and SRVR.
Loading charts...
Drawdown Indicators
| GNOM | SRVR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -40.99% | -34.01% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -14.78% | -3.39% |
Max Drawdown (3Y)Largest decline over 3 years | -46.47% | -18.34% | -28.13% |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | -40.99% | -31.30% |
Current DrawdownCurrent decline from peak | -55.45% | -12.28% | -43.17% |
Average DrawdownAverage peak-to-trough decline | -40.55% | -15.27% | -25.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.30% | 6.83% | -0.53% |
Volatility
GNOM vs. SRVR - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.47% compared to Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF (SRVR) at 5.47%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than SRVR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM | SRVR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.47% | 5.47% | +3.00% |
Volatility (6M)Calculated over the trailing 6-month period | 19.44% | 13.12% | +6.32% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.50% | 16.72% | +9.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.57% | 19.71% | +13.86% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.17% | 21.44% | +12.73% |
GNOM vs. SRVR - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is lower than SRVR's 0.60% expense ratio.
Dividends
GNOM vs. SRVR - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.27%, less than SRVR's 2.70% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 1.27% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% |
SRVR Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF | 2.70% | 2.67% | 2.00% | 3.69% | 1.70% | 1.19% | 1.59% | 1.61% | 2.13% |
Frequently Asked Questions
GNOM and SRVR have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GNOM has higher volatility (8.47%) compared to SRVR (5.47%). In terms of maximum drawdown, GNOM dropped -75.00% vs SRVR's -40.99%.
On 5-year performance, SRVR leads with -0.81% vs -10.20% for GNOM. On fees, GNOM is cheaper at 0.50% per year. On volatility, SRVR has been the lower-risk option at 5.47%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, SRVR has performed better with a -0.81% return vs -10.20%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
GNOM is cheaper with a 0.50% expense ratio, compared with 0.60% for SRVR.
SRVR has the higher dividend yield at 2.70%, compared with 1.27% for GNOM.
GNOM is categorized as Health & Biotech Equities, while SRVR is REIT. GNOM tracks Solactive Genomics Index, while SRVR tracks Benchmark Data & Infrastructure Real Estate SCTR Index. They also come from different issuers: Global X and Pacer. Their fees differ too: 0.50% for GNOM and 0.60% for SRVR.
GNOM currently has the higher Sharpe Ratio (2.06 vs 0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GNOM and SRVR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer